The present invention relates to a combination which comprises (a) a FGFR inhibitor and (b) a glucocorticoid receptor modulator, or a pharmaceutical acceptable salt thereof; the use of such a combination for the preparation of a medicament for the treatment of haematological cancers; a commercial package or product comprising such a combination; and to a method of treatment of a warm-blooded animal, especially a human.
Claims: A combination of (a) a FGFR inhibitor and (b) a modulator of glucocorticoid receptor, wherein (a) and (b) are present in each case in free form, complex form or in the form of a pharmaceutically acceptable salt.
Novartis Oncology currently has two FGFR
inhibitors in development: Dovitinib (TKI258) and BGJ398
•Phase I/II (Confirmatory) - Breast Cancer
•Phase I/II (Confirmatory) - Endometrial cancer
•Phase I/II (Confirmatory) - Hepatocellular carcinoma
•Phase III or Pivotal (Registration Trials) - Renal cell carcinoma (RCC)
Mode of Action: FGFR inhibitor
Tumor Type: Solid
One lung cancer patient with an FGFR1/CEP8 ratio of 2.6 by FISH analysis responded to 100 mg of NVP-BGJ398 with a 33% reduction in target lesions by CT scan at 8 weeks, confirmed at 12 weeks, and a substantial SUV decrease on PET. These observations provide early evidence that inhibition of the FGFR pathway is effective in patients with FGFR dependent cancers.